Suppr超能文献

结节性淋巴瘤:当前概念

Nodular lymphomas: current concepts.

作者信息

Matis L A, Young R C, Longo D L

出版信息

Crit Rev Oncol Hematol. 1986;5(2):171-97. doi: 10.1016/s1040-8428(86)80024-5.

Abstract

The past several years have witnessed innovative approaches to clinical management as well as significant insights into the basic biology of the nodular lymphomas. Clinical studies have explored two apparently widely disparate approaches to the treatment of patients with nodular lymphoma. On the one hand, withholding initial therapy (watch and wait) has proved to be a viable option in the management of some patients. This approach has provided information regarding the natural history of disease, such as the relative incidence of spontaneous tumor regression vs. histologic transformation to more aggressive forms of lymphoma. Alternatively, recent data also suggest that the administration of intensive chemotherapy, shown to induce long-term remissions in a high percentage of patients with diffuse aggressive lymphomas, may also produce a significant number of durable remissions in at least certain histologic subtypes of nodular lymphomas. Clinical studies which attempt to achieve a synthesis of the above two approaches are currently in progress. Advances in immunology and molecular biology have also found application in the study of nodular lymphoma. Monoclonal antibodies have been employed diagnostically, as, for example, in detecting small numbers of persistent abnormal lymphoid clones in patients in apparent remission, and therapeutically, as exemplified by the clinical use in vivo of monoclonal antibodies directed against unique idiotypic determinants expressed by surface immunoglobulin on the malignant B lymphocytes. The demonstration of the immunoglobulin gene rearrangements in nodular lymphoma cells has established a more definitive criterion for their phenotypic characterization. Finally, molecular cloning of the breakpoint of the t(14; 18) chromosome translocation frequently found in nodular lymphoma cells has led to the identification of a potential new transforming gene which could be activated as a direct consequence of its rearrangement in proximity to the immunoglobulin in heavy chain gene locus.

摘要

在过去几年中,临床管理出现了创新方法,同时对结节性淋巴瘤的基础生物学也有了重要认识。临床研究探索了两种明显不同的结节性淋巴瘤患者治疗方法。一方面,延迟初始治疗(观察等待)已被证明是某些患者管理中的可行选择。这种方法提供了有关疾病自然史的信息,例如自发肿瘤消退与组织学转化为更具侵袭性淋巴瘤形式的相对发生率。另一方面,最近的数据还表明,对弥漫性侵袭性淋巴瘤患者显示能诱导高比例长期缓解的强化化疗,在至少某些组织学亚型的结节性淋巴瘤中也可能产生大量持久缓解。目前正在进行试图综合上述两种方法的临床研究。免疫学和分子生物学的进展也已应用于结节性淋巴瘤的研究。单克隆抗体已用于诊断,例如在明显缓解的患者中检测少量持续存在的异常淋巴克隆,也用于治疗,如针对恶性B淋巴细胞表面免疫球蛋白表达的独特个体决定簇的单克隆抗体在体内的临床应用。结节性淋巴瘤细胞中免疫球蛋白基因重排的证明为其表型特征建立了更明确的标准。最后,在结节性淋巴瘤细胞中经常发现的t(14; 18)染色体易位断点的分子克隆导致鉴定出一种潜在的新转化基因,其可能因其在重链基因位点与免疫球蛋白接近处的重排而直接被激活。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验